about PharmaEngine

PharmaEngine focuses on the development of new medications for the treatment of cancer and Asian prevalent diseases. There are 3 projects in the pipeline: ONIVYDEâ(PEP02, MM-398, nal-IRI) was approved by the US FDA, Taiwan FDA and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; PEP503 (NBTXR3) is in a global pivotal clinical study of soft tissue sarcoma; PEP06 is in the lead optimization.